Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Rika, Kouhashi"'
Autor:
Rika, Kouhashi, Shinichiro, Kashiwagi, Yuko, Kawano, Akimichi, Yabumoto, Sae, Ishihara, Wataru, Goto, Yuka, Asano, Yukie, Tauchi, Tamami, Morisaki, Satoru, Noda, Tsutomu, Takashima, Kosei, Hirakawa, Masaichi, Ohira
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(13)
Pertuzumab plus trastuzumab plus docetaxel regimen is the first choice for the initial treatment of HER2-positive recurrent breast cancer. However, docetaxel causes many adverse events. A 48-year-old woman was admitted to our hospital for a left brea
Autor:
Wataru Goto, Akimichi Yabumoto, Masaichi Ohira, Shinichiro Kashiwagi, Tamami Morisaki, Koji Takada, Tsutomu Takashima, Kosei Hirakawa, Masahiko Ohsawa, Yuka Asano, Sayaka Tanaka, Rika Kouhashi
Publikováno v:
Anticancer research. 40(6)
BACKGROUND/AIM In addition to its cytocidal effects as a microtubule dynamics inhibitor, eribulin mesylate (eribulin) regulates the tumour microenvironment. We examined the clinical significance of tumour infiltrating lymphocytes (TILs) and transform
Autor:
Yuka, Asano, Shinichiro, Kashiwagi, Rika, Kouhashi, Koji, Takada, Wataru, Goto, Sae, Ishihara, Yukie, Tauchi, Tamami, Morisaki, Satoru, Noda, Tsutomu, Takashima, Naoyoshi, Onoda, Kosei, Hirakawa, Masaichi, Ohira
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(13)
In the treatment of advanced breast cancer, onlya few drugs confer overall survival(OS)benefit. Eribulin is a drug that was shown to extend OS in an international phase Ⅲtrial; however, the underlying mechanism is thought to involve cancer microenv